Christopher Haqq - Insider Trading & Ownership

Entity
Individual
Location
C/O Atara Biotherapeutics, Inc., 3260 Bayshore Boulevard, Brisbane, California
Summary
The estimated net worth of Christopher Haqq is at least $197K dollars as of February 5, 2024. Christopher Haqq is the Title: Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, Inc. and owns shares of Elicio Therapeutics, Inc. (ELTX) stock worth about $186K. Christopher Haqq is the Former Director of Surrozen, Inc./DE and owns shares of Surrozen, Inc./DE (SRZN) stock worth about $11.4K.
All Insider Reports
All Insider Reports

Ownership of Christopher Haqq

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
ELTX Elicio Therapeutics, Inc. Title: Executive Vice President, Head of R&D and Chief Medical Officer $186K Feb 1, 2024
SRZN, SRZNW Surrozen, Inc./DE Former Director $11.4K Aug 11, 2021

Insider Transactions Reported by Christopher Haqq:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.